Search

Displaying results 5321 - 5330 of 7181 in total
  1. Drug

    OPC-14523

    go.drugbank.com/drugs/DB05422
    Experimental

    OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.

  2. Drug

    acetylleucyl-leucyl-norleucinal

    go.drugbank.com/drugs/DB07558
    Experimental

    Synonyms: N-Ac-Leu-leu-norleucinal, N-acetylleucylleucylnorleucinalCategories: NF-kappa B, antagonists & inhibitors
  3. Drug

    Razuprotafib

    go.drugbank.com/drugs/DB16353
    Investigational

    Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP. … [L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.

  4. Drug

    Lanoteplase

    go.drugbank.com/drugs/DB06245
    Experimental

  5. Drug

    Tariquidar

    go.drugbank.com/drugs/DB06240
    Investigational

  6. Drug

    MDL72527

    go.drugbank.com/drugs/DB04188
    Experimental

    Categories: Oxidoreductases Acting on CH-NH Group Donors, antagonists & inhibitors
  7. Drug

    TAK-475

    go.drugbank.com/drugs/DB05317
    Investigational

    TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.

  8. Drug

    ND1251

    go.drugbank.com/drugs/DB05132
    Experimental

    ND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression.

  9. Drug

    Sumanirole

    go.drugbank.com/drugs/DB06477
    Investigational

  10. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition